Agios Pharmaceuticals

The Agios Pharmaceuticals - developer in the field of cellular metabolism who is engaged in development of experimental medicines for treatment of oncohematological diseases, solid tumors and rare genetic diseases. In addition to actively researched and searching for new drugs in these three therapeutic areas, Adjios also has two approved oncological drugs for personalized therapy and a number of the first experimental drugs in its group in the clinical and (or) preclinical research stage.

History

2021: Servier completes acquisition of Adjios Pharmaceuticals oncology unit

The international pharmaceutical company "" Servye on April 5, 2021 announced the successful completion of the transaction to acquire the portfolio of oncological drugs of the company "Adjios Pharmaceuticals" - both already released on the market and currently under clinical research and development. The deal amounted to about $2  billion, and also involves licensing fees.

According to Servier's expectations, this acquisition will allow the company to strengthen its position in the market for drugs for the treatment of oncohematological diseases in the United States and provide potential for long-term growth in the field of solid tumor therapy.

"We are pleased to welcome the Ajios team of professionals as part of the Servier Group. Together, we will strengthen our positions in the field of oncology and expand the potential in the field of research on cellular metabolism, "said Olivier Loro, president of the Servier group. - This is an important step for the development of the company, which will significantly strengthen our presence in the US market. Together, we will continue to seek solutions to meet the needs of cancer patients around the world. "

As part of this transaction, Adjios employees in the United States working with the company's cancer drugs will become part of the Servier Pharmaceuticals team, the Servier division in the United States.

"We highly appreciate the support of our employees, partners and colleagues from Adjios - thanks to this, the association is as effective as possible," said David K. Lee, CEO of Servier in the United States. - Expanding our portfolio through drugs ivosidenib and enasidenib will strengthen the position in the cancer drug market in the United States and accelerate the development of new therapies for patients with oncohematological diseases, including acute myeloid leukemia. "

As specified in the message "Servier," the company transferred the existing portfolio of oncological drugs of the company "Adjios," the portfolio of drugs in the development and research programs.

Under the terms of the transaction, Adjios received an advance payment of $1.8 billion from Servier, and also has the right to receive an additional $200 million if the results for medicines in development are achieved. In addition, as part of the transaction, license payments are provided. The transaction was approved by the boards of directors of both companies, as well as shareholders of Adjios. All necessary regulatory approvals were obtained under this transaction.

2020: Servier acquires the oncology division of Agios Pharmaceuticals for $2 billion

In December 2020, the pharmaceutical company Servier informed Zdrav.Expert about the conclusion of an agreement on the acquisition of the oncology division of Agios Pharmaceuticals. Under the terms of the agreement, Servier will move to a portfolio of oncological drugs - both already released on the market and currently under clinical research and development. We are talking about a commercial, clinical and research portfolio of cancer treatment drugs that are in the third stage of clinical trials, as well as the approved drug TIBSOVO. The purchase cost will be $2 billion: this amount includes an advance payment of $1.8 billion and an additional $200 million after resolving regulatory issues. In addition, license payments are provided.

Servier buys out Agios oncology unit for $2 billion

The transaction was approved by the boards of directors of both companies. If authorized by the regulatory bodies and approved by the shareholders of Agios. It is assumed that the transaction will be closed in the second quarter of 2021.^[1]

This acquisition will allow the Servier group to strengthen its portfolio of drugs and developments in the field of oncology. Given the existing unmet medical needs in the field of oncology, Servier management decided to make this area one of its strategic priorities, allocating 50% of the total budget for research and development to this area. The deal will significantly strengthen Servier's position in the US market, where the company has been present since 2018.

The acquisition of the oncology division of Agios is of strategic importance to us: it includes a portfolio of drugs for personalized therapy, both already released on the market and in development. Thus, we have become one step closer to our goal - to become a significant player in the cancer drug market. This acquisition will allow us to continue to offer solutions for patients with cancer. This is a very important event for the Servier group of companies - we will be able to significantly strengthen our position in the USA and expand the opportunities in the field of research and development of oncological drugs. We are pleased to welcome the professional Agios team that will join Servier after the deal is completed. noted Olivier Loro, President of Servier.

Agios is one of the representatives in the study of cellular metabolism and has experience in the development and marketing of drugs for personalized therapy. The acquisition of the Agios oncology division involves the transfer to Servier of specialists from the research and development, technical and operational departments, which will allow us to expand our expertise in the field of other oncohematological diseases in the United States. In addition, we will gain potential for long-term growth in the field of solid tumor therapy. Thus, we will be able to provide care to even more cancer patients with unmet medical needs. commented David C. Lee, Chief Executive Officer of Servier, Servier's U.S. affiliate.

The sale of Servier's oncology portfolio is one of the transformation stages for Agios. We are proud of our achievements in the field of oncology and drugs developed for the treatment of patients with oncohematological diseases and solid tumors. We are pleased that our oncology portfolio is moving to Servier, an international pharmaceutical company focused on patients. Servier is committed to contributing to the treatment of cancer patients and will continue to invest in our resources and our employees. This transaction will allow our portfolio to develop with Servier. emphasized Jackie Foles, PhD, chief executive officer of Agios.

The deal includes the transition of the Agios oncology portfolio and associated employees, including the drug ivosidenib present on the market for December 2020. This drug is allowed for use in the USA as a monotherapy for the treatment of adult patients with recurrent or refractory form of acute myeloid leukemia (AML) with the IDH1 mutation, as well as the treatment of adult patients with the first diagnosed AML with the IDH1 mutation, aged 75 years and older or with concomitant diseases that exclude the use of intensive induction chemotherapy. Ivosidenib is also being studied in two studies of the combined use of phase III drugs involving patients with first-time diagnosed AML, and as a possible therapy for patients with cholangiocarcinoma and myelodysplastic syndrome (MDS) with the IDH1 mutation previously treated. As part of the transaction, Servier will also acquire Agios' obligations to jointly sell the drug IDHIFA (enasidenib) to Bristol Myers Squib and will conduct certain clinical developments in accordance with the research program for this drug.

In addition, the deal includes Agios' portfolio of cancer drugs under development and current clinical research programs. The drugs under study include vorasidenib, an experimental double inhibitor of mutant forms of IDH1 and IDH2, which as of December 2020 is being studied in a phase III INDIGO registration study involving patients with low-malignancy glioma with an IDH mutation. It also includes AG-270, an experimental inhibitor of methionine-adenosyltransferase 2a (MAT2A), the use of which is evaluated in combination with taxanes in patients with non-small cell lung cancer and pancreatic cancer with missing methylthioadenosine phosphorylase (MTAP). Also as part of the deal, AG-636, a dihydroorotate dehydrogenase inhibitor (DHODH) and Agios oncology research programs will go to Servier.

All Agios employees in the United States, working mainly in the oncology division, will receive a decent offer from Servier.

Notes